Industry And Regulators Thrash Out Brexit Concerns At Stakeholder Meeting
Regulators and industry shared their concerns about preparedness, legal uncertainties and the regulatory and supply chain implications of Brexit at a recent stakeholder meeting at the European Medicines Agency.
You may also be interested in...
The EMA has completed the reallocation to the EU27 member states of more than 370 centrally authorized drugs for which the UK was rapporteur or co-rapporteur. The move has been necessitated by Brexit, which means the UK will no longer play an active role in new drug evaluations at the EMA.
Pharmaceutical companies have been urged by the European Commission to press ahead with their contingency planning for Brexit, amid signs some firms are taking a “wait-and-see” approach.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.